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We have previously showed that, despite the significant reduc-
tion of transplant-related mortality (TRM) achieved by using
reduced intensity conditioning (RIC), relapse continues to be a ma-
jor cause of failure, especially in advanced-stage hematologic ma-
lignancies. In order to improve relapse-free survival in the setting
of reduced intensity sibling donor transplants for advanced hema-
tologic malignancies, our group has tested a modified Fludara-
bine/Busulfan RIC regimen (fludarabine 150 mg/m2 IV, busulfan
6 mg/kg IV, total lymphoid irradiation 2 Gy) with a rapid post-
transplant immunosuppression (IS) taper (start day 28, finish day
63) in a prospective single arm phase II study. The rapid taper
was intended to facilitate a GVL effect that hopefully would trans-
late into improved DFS. Patients without progression who did not
develop GVHD by d100 received planned donor lymphocyte infu-
sion (DLI) 5  107 CD31/kg. 45 pts (median f/u 918d; range 100–
1835d) have been treated between 8/2003- 2/2008. The median age
was 56y (2–67y); 19 (42%) failed previous autologous HCT. Five
patients received DLI. Forty patients received HSC from 6/6
HLA matched and 5 from 5/6 HLA matched related donors. Rapid
tacrolimus taper reliably induced GVHD grade 2–4 in the study
population (73 6 6%) by day 100 at a median of 46d (range, 18–
98d). Extensive chronic GVHD developed in 6567% of patients.
GVHD in this context was rarely fatal (7 GVHD-related deaths) re-
sulting in 2-year NRM of 24 6 7%. Outcomes were analyzed for
the whole group and by stratification according to risk of relapse af-
ter non-myeloablative HSCT.Stratification of the Study Patients According to the Esti-
mated Risk of Relapse After NMA HSCT (1)
High/Standard-risk disease n528 Low-risk disease n517
AML (de novo) 4 Follicular lymphoma, low grade 4
AML (secondary) 3 MAntle cell lymphoma 4
AML (treatment-related) 2 DLBCL/t-DLBCL, CR 3
MDS 6 NHL/AITL, CR 1
CML-BC 1 MM, CR 5
Ph1ALL, CR2 1
Hodgkin’s disease, refractory 4
MM, refractory 5
t-DLBCL, refractory 1
CLL, refractory 1
(1)-kahl, c., et al. Bood 2007; 110:7 2744-48The 2-year OS and PFS for all pts was 38617% and 3567% re-
spectively, with superior PFS seen in low risk vs high/standard
risk pts (526 13% vs 2668% p 5 0.03). A higher cumulative in-
cidence of progression in high/standard risk pts (6369% vs 0%,
p5 0.0001) accounted for most of the difference in survival. How-
ever, when compared to similar risk group pts in our prior trial
(Levine, et al, BBMT 2003) that utilized identical conditioning,
but a conventional IS taper, there were no differences in PFS for
low risk (58% vs 50%, p 5 NS) or high risk pts (29% vs 23%,
p 5 NS). TRM rates were similar in both trials (32% vs 24%,
p 5NS). Thus, while a rapid IS taper in this RIC setting induces
GVHD that is usually non-lethal, the desired GVL effect did not
manifest itself in terms of improvements in PFS for low or high
risk pts.
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Background: Patients undergoing hematopoietic stem cell or
bone marrow transplants (HSC/BMTs) are at an increased risk of
contracting invasive fungal infections (IFIs). Data on the economic
burden of these infections are sparse.Methods: This retrospective matched cohort study used data
from the 2004 and 2005 Healthcare Cost and Utilization Pro-
ject Nationwide Inpatient Sample (HCUP-NIS) to assess the
excess mortality, lengths of stay, and costs of IFIs in HSC/
BMT recipients. Patients were selected for the IFI cohort if
they had ICD-9-CM codes indicating an HSC/BMT procedure
and an IFI during their hospital stay. Patients were matched to
controls (transplant recipients who had no diagnosis of IFI)
based on age (within 10 years), sex, hospital region, hospital
type, year in hospital (2004 or 2005), and type of transplant (al-
logeneic HSC/BMT, or autologous HSC/BMT). Analyses of
mortality, lengths of stay, and costs were reported overall and
by type of transplant.
Results: In 2004 and 2005, 4,661 patients received an HSC or
BMT. Of these, 111 (2.4%) had a diagnosis of an IFI in hospi-
tal. Almost all IFI patients (98%) could be matched to controls.
After matching, the mean (6SD) age was 37.8 (621.6) years,
62% of patients were male, and patients were predominately
white. Common comorbidities among patients with an HSC/
BMT and an IFI included fluid and electrolyte disorders
(46.8%), hypertension (16.5%), and coagulopathy (13.8%). As-
pergillosis was the most common type of mycosis followed by
candidiasis. Overall, IFIs in HSC/BMT recipients were associ-
ated with a 6-fold increase in mortality (23.2% among patients
with IFIs vs 3.8% among patients without IFIs), excess mean
(6SD) lengths of stay of 16.2 (65.0) days, and excess mean
(6SD) costs of $51,655 (6$12,399) per patient. Patients with
allogeneic HSC/BMT had higher excess mortality and excess
lengths of stay but lower excess costs than patients with autol-
ogous HSC/BMT.
Conclusions: The excess burden of IFIs among HSC/BMT re-
cipients is high. Improved efforts to prevent these infections may
yield both clinical and economic benefits.14
STANDARD AND REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATIONS (HSCT) FROM RELATED AND UNRE-
LATED DONORS FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).
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This retrospective analysis concerned 374 patients (pts) who un-
derwent an allo-HSCT for CLL reported to the EBMT registry.
There were 282 M and 92 F, median age 53 years (24–69). The in-
terval diag-transp. was 53 months (3–308). Forty five pts (12%)
have received a previous HSCT. At transplant, 302 among 323
evaluated pts had a good performance status (PS) (93%), 51 pts
were in CR (14%), 163 in PR (45.5%), 39 in SD (11.5%) and
105 in PD (29%) among 353 evaluated pts. As conditioning, 292
pts received a standard (std) one and 82 RIC; 314 pts received
PBSC, 55 BM and 5 cord blood cells from 202 HLA siblings
(Sib), 2 mismatched related donors and 170 unrelated donors
(UD). There were 136 (36%) sex-mismatched, 150 pairs (40%)
had an ABO incomp. (61 min., 99 maj.). There were 359 pts en-
grafted, 201 AGVHD (gr I: 76, gr II : 79 , gr III: 30 and gr
IV:16) and 15 cGVHD (75 lim., 78 ext.). At day 100, the cumula-
tive incidence (CI) of AGVHD for the total population was 17%
(13–22) for gr I, 31% (26–36) for gr $ II. [Sib: 19% (13–25) gr
I and 27% (21–34) gr $ II; UD: 16% (9–22) gr I and 38%
(29–47) gr $ II].
